Etoposide in malignant pleural mesothelioma: two phase II trials of the EORTC Lung Cancer Cooperative Group

Autor: Tarek Sahmoud, Karin Mattson, L. Tammilehto, J. van Pawel, Andrea Ardizzoni, K. J. Roozendaal, A.S.T. Planting, M. Schrijver, G. Giaccone, N. van Zandwijk, Anne Kirkpatrick, Ted A.W. Splinter, T. Sutedja, Pe Postmus, Paul Baas, C. van Pottelsberghe, M. van Glabbeke

Publikováno v: European Journal of Cancer, 33, 2211-2215. Pergamon
European Journal of Cancer, 33(13), 2211-2215. Elsevier Ltd.
European Journal of Cancer, 33(13), 2211-2215. ELSEVIER SCI LTD
Sahmoud, T, Postmus, P E, van Pottelsberghe, C, Mattson, K, Tammilehto, L, Splinter, T A W, Planting, A S T, Sutedja, G, van Pawel, J, van Zandwijk, N, Baas, P & Roozendaal, K J 1997, ' Etoposide in malignant pleural mesothelioma: two phase II trials of the EORTC Lung Cancer Cooperative Group ', European Journal of Cancer, vol. 33, pp. 2211-2215 . https://doi.org/10.1016/S0959-8049(97)00183-4

Intravenous and oral etoposide (VP 16-213) were tested in two sequential phase II trials in chemotherapy-naive patients with malignant pleural mesothelioma. In the first trial, etoposide was given intravenously (i.v.) at a dose of 150 mg/m(2) on days

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::80e4fa9a8a3bd6cc3be1125ee25c9b38
https://research.vumc.nl/en/publications/b694fdb6-c566-4e28-baa3-505d3f8ebac7

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.